Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > My opinion

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 04, 2021 8:27pm

162 Views

Post# 33965166

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:My opinion

The extension of PFS to 27 months is impressive. This is 2L and HER2+ breast cancer is about 20% of cases.
Great news for patients. It seems it's becoming the standard for HER2+. Given the targeting issues, I guess Enhertu will only work for the HER2+ subset so may not be useful for THTX to attach for all solid tumors in 4L setting. But those numbers would be something to shoot for!

qwerty22 wrote:
One MD gushing over Enhurtu.

https://www.medpagetoday.com/meetingcoverage/esmovideopearlsmetbreastca/94758

qwerty22 wrote: Enhurtu. Must be putting pressure on all those breast cancer only drug developers. Hopefully we get breast+another.

"The FDA has granted breakthrough designation to AstraZeneca's and Daiichi Sankyo's HER2 ADC Enhertu, the companies jointly announced today.

The BTD is for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens.

Breakthrough therapy designation was based on data from the DESTINY-Breast03 pivotal trial at #ESMO21 just last month, which showed a 72% reduction compared to Roche’s ADC Kadcyla in the risk of disease progression or death in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

“This is an important step in bringing Enhertu as a potential new option in earlier lines of treatment for HER2 positive metastatic breast cancer, given the urgent need to improve outcomes,” said AstraZeneca EVP of oncology R&D Susan Galbraith in a statement.

Previous BTDs for the drug were in late-line HER2 positive metastatic breast cancer in 2017 and HER2 mutant metastatic non-small cell lung cancer (NSCLC) and HER2 positive metastatic gastric cancer in 2020."